Evidence map›Paper›PMID 29443062›Full record

ArticleJournal of visualized experiments : JoVE2018

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood.

Marie-Claire Devilder, Mélinda Moyon, Xavier Saulquin, Laetitia Gautreau-Rolland

Abstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Marie-Claire DevilderCentre Régional de Recherche en Cancérologie et Immunologie Nantes/Angers, INSERM 1232, LabEx IGO, Université de Nantes; CHU Nantes.
Mélinda MoyonCentre Régional de Recherche en Cancérologie et Immunologie Nantes/Angers, INSERM 1232, LabEx IGO, Université de Nantes; CHU Nantes.
Xavier SaulquinCentre Régional de Recherche en Cancérologie et Immunologie Nantes/Angers, INSERM 1232, LabEx IGO, Université de Nantes; Xavier.Saulquin@univ-nantes.fr.
Laetitia Gautreau-RollandCentre Régional de Recherche en Cancérologie et Immunologie Nantes/Angers, INSERM 1232, LabEx IGO, Université de Nantes; Laetitia.Gautreau@univ-nantes.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal antibodies (mAbs) are powerful tools useful for both fundamental research and in biomedicine. Their high specificity is indispensable when the antibody needs to distinguish between highly related structures (e.g., a normal protein and a mutated version thereof). The current way of generating such discriminative mAbs involves extensive screening of multiple Ab-producing B cells, which is both costly and time consuming. We propose here a rapid and cost-effective method for the generation of discriminative, fully human mAbs starting from human blood circulating B lymphocytes. The originality of this strategy is due to the selection of specific antigen binding B cells combined with the counter-selection of all other cells, using readily available Peripheral Blood Mononuclear Cells (PBMC). Once specific B cells are isolated, cDNA (complementary deoxyribonucleic acid) sequences coding for the corresponding mAb are obtained using single cell Reverse Transcription-Polymerase Chain Reaction (RT-PCR) technology and subsequently expressed in human cells. Within as little as 1 month, it is possible to produce milligrams of highly discriminative human mAbs directed against virtually any desired antigen naturally detected by the B cell repertoire.

Indexed as

Antibodies, MonoclonalB-LymphocytesFlow CytometryHumansAntibodies, Monoclonal

Identifiers

PMID29443062
PMCPMC5912359

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.